VaccibodyAs Financial Statements From 2010 to 2024
| VACCDelisted Stock | USD 4.91 0.31 6.74% |
Check VaccibodyAs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among VaccibodyAs main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . VaccibodyAs financial statements analysis is a perfect complement when working with VaccibodyAs Valuation or Volatility modules.
VaccibodyAs |
VaccibodyAs Company Return On Equity Analysis
VaccibodyAs' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current VaccibodyAs Return On Equity | -0.23 |
Most of VaccibodyAs' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VaccibodyAs is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, VaccibodyAs has a Return On Equity of -0.2329. This is 99.03% lower than that of the Biotechnology sector and 99.36% lower than that of the Health Care industry. The return on equity for all Norway stocks is 24.87% lower than that of the firm.
VaccibodyAs Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining VaccibodyAs's current stock value. Our valuation model uses many indicators to compare VaccibodyAs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across VaccibodyAs competition to find correlations between indicators driving VaccibodyAs's intrinsic value. More Info.VaccibodyAs is rated fifth in return on equity category among related companies. It is rated below average in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value VaccibodyAs by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for VaccibodyAs' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the VaccibodyAs' earnings, one of the primary drivers of an investment's value.About VaccibodyAs Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include VaccibodyAs income statement, its balance sheet, and the statement of cash flows. VaccibodyAs investors use historical funamental indicators, such as VaccibodyAs's revenue or net income, to determine how well the company is positioned to perform in the future. Although VaccibodyAs investors may use each financial statement separately, they are all related. The changes in VaccibodyAs's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on VaccibodyAs's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on VaccibodyAs Financial Statements. Understanding these patterns can help to make the right decision on long term investment in VaccibodyAs. Please read more on our technical analysis and fundamental analysis pages.
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom. Vaccitech Plc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards VaccibodyAs in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, VaccibodyAs' short interest history, or implied volatility extrapolated from VaccibodyAs options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the VaccibodyAs information on this page should be used as a complementary analysis to other VaccibodyAs' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in VaccibodyAs Stock
If you are still planning to invest in VaccibodyAs check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the VaccibodyAs' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |